If you can’t beat them, join them. This appears to be the view of Johnson & Johnson, which is teaming up with its arch anticoagulant rival, Bristol-Myers Squibb, to develop a next-generation blood thinner.
J&J thinks there is plenty of life left in its stalwart Xarelto, but the Bristol deal means that it is already looking to the future, with two mid-stage projects that it believes could offer similar efficacy but better safety. The company needs to stay ahead of the game if it is to fill a looming Xarelto-shaped hole – the drug, which is set to come off patent in 2024, is forecast to breach the $9bn barrier by 2022 along with Bristol-Myers Squibb/Pfizer’s rival Eliquis (see table below).
But any would-be Xarelto heirs will need to show more than just an incremental benefit if they are to justify a premium price, and the pressure is now on J&J to deliver (Vantage Point – Solving the incremental innovation dilemma, March 15, 2018).
Jim List, head of cardiovascular and metabolism in J&J’s Janssen division, is adamant that there is no reason to panic, telling EP Vantage: “We’re still investing very heavily in Xarelto, and we see great potential here – not only for the current indications, but also potential future indications. But we’re also building for the future at the same time.”
One of J&J’s new bets, the oral factor XIa inhibitor BMS-986177, comes from this week’s deal with Bristol. The compound is set to enter a phase II trial this year in secondary stroke prevention, joining several other mid-stage projects targeting targeting factor XI or XIa.
This is an area where Bayer – J&J’s partner for Xarelto – is particularly well represented, boasting the monoclonal antibody BAY 1213790 and the antisense project IONIS-FXIRx, licensed from Ionis.
|Factor XI(a) projects in active development|
|BAY 1213790||Bayer||Anti-factor XIa MAb||Foxtrot, NCT03276143 (knee replacement)||Apr 2019|
|BAY 2306001/IONIS-FXIRx||Ionis/Bayer||Factor XI antisense||NCT03358030 (ESRD)||Jun 2019|
|MAA868||Novartis||Anti-factor XI MAb||NCT03398434 (atrial fib); NCT03393481 (knee replacement)||Jul 2019; Oct 2019|
|BMS-986177||Bristol-Myers Squibb/Johnson & Johnson||Oral factor XIa inhibitor||Phase II to begin 2018||-|
|EP-7041||Exithera Pharmaceuticals||IV factor XIa inhibitor||NCT02914353||Data presented Nov 2017|
|IONIS-FXI-LRx||Ionis/Bayer||Factor XI ligand conjugated antisense||-||-|
|AB022||Aronora||Anti-factor XIa MAb||-||-|
|BMS-262084||Bristol-Myers Squibb||IV/oral factor XIa Inhibitor||-||-|
|BMS-962212||Bristol-Myers Squibb||IV factor XIa inhibitor||-||-|
|ESRD: end-stage renal disease. Source: EvaluatePharma.|
J&J and Bristol did not give financial details of their collaboration, but a spokesperson for Bristol told EP Vantage that the companies would share development and commercialisation costs and any future profits, “roughly 50/50”, and that, if BMS-986177 is approved, Bristol would expect to book US sales and Janssen ex-US revenues.
While Bristol also has two other factor XIa projects in its pipeline, the company is currently prioritising BMS-986177, the spokesperson said, adding that it was not looking at other antithrombotic mechanisms outside factor XIa.
J&J is not putting all its eggs in one basket, though – it is also working on another next-gen anticoagulant, JNJ-9375, which it gained via its acquisition of XO1 in 2015. That project, a monoclonal antibody against exosite 1 thrombin, is already in a phase II trial in patients undergoing knee replacement surgery, due to be completed next year.
“We have two very good shots on goal; they’re very different,” says Mr List, pointing out that the oral BMS-986177 will likely be dosed daily, while JNJ-9375 will probably be a monthly injection.
The idea is that the next-generation approaches could give equivalent or better efficacy versus the likes of Xarelto, but with a lower risk of side effects, particularly bleeding events. Indeed, an increased incidence of bleeding took the edge off last year’s win in the Compass trial in coronary and peripheral artery disease.
Still, J&J hopes for an expanded label on the back of the Compass data, with a decision due by the end of the year. And Xarelto’s bleeding risk has not hindered a steady rise in analyst forecasts in the past year. While an EP Vantage analysis carried out in September had Bristol-Myers Squibb/Pfizer’s Eliquis overtaking Xarelto by 2022, sellside consensus now has Xarelto back in front (Spotlight – Xarelto and Eliquis's blood feud, September 12, 2017).
|Xarelto vs Eliquis|
|Sales forecasts ($bn)|
|Product||Companies||2018||2019||2020||2021||2022||12-mth rise in 2022 forecast*|
|Xarelto||Bayer/Johnson & Johnson||6.5||7.4||8.3||9.1||9.9||11%|
|*Current 2022 vs consensus in April 2017; Source: EvaluatePharma.|
But J&J’s label-expansion efforts have not always gone smoothly: Navigate Esus, in secondary stroke prevention, was stopped for futility in October. J&J is to report three more key label-extension trials this year: Mariner, Commander and Cassini.
BMS-986177, meanwhile, will also be studied in indications outside secondary stroke prevention. Neither J&J nor Bristol is giving details for now, but Mr List hinted that this could be a large development programme: “We’re not going to be shy in phase II or III.”
J&J has ploughed a huge amount of cash into expanding Xarelto’s reach, but sales cannot keep growing forever. The question now is whether BMS-986177 or JNJ-9375 can show a better safety profile – and, if they can, whether this will be enough to get payers to cough up once Xarelto goes generic.
|Upcoming Xarelto label-expansion readouts|
|Study||Setting||Trial ID||Primary completion|
|Mariner||Prevention of VTE in post-hospital discharge high-risk patients||NCT02111564||May 2018|
|Commander HF||Prevention of major cardiovascular events in heart failure patients||NCT01877915||May 2018|
|Cassini||Prevention of VTE in cancer patients||NCT02555878||July 2018|